1. The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR+ CD8+ effector state, and its deletion improves checkpoint blockade.
- Author
-
McClory, Susan E., Bardhan, Oishi, Rome, Kelly S., Giles, Josephine R., Baxter, Amy E., Xu, Lanwei, Gimotty, Phyllis A., Faryabi, Robert B., Wherry, E. John, Pear, Warren S., and Jordan, Martha S.
- Abstract
CD8
+ T cell exhaustion (T EX) impairs the ability of T cells to clear chronic infection or cancer. While T EX are hypofunctional, some T EX retain effector gene signatures, a feature associated with killer lectin-like receptor (KLR) expression. Although KLR+ T EX (T KLR) may improve control of chronic antigen, the signaling molecules regulating this population are poorly understood. Using single-cell RNA sequencing (scRNA-seq), flow cytometry, RNA velocity, and single-cell T cell receptor sequencing (scTCR-seq), we demonstrate that deleting the pseudokinase Trib1 shifts T EX toward CX3CR1+ intermediates with robust enrichment of T KLR via clonal T cell expansion. Adoptive transfer studies demonstrate this shift toward CD8+ T KLR in Trib1-deficient cells is CD8 intrinsic, while CD4-depletion studies demonstrate CD4+ T cells are required for improved viral control in Trib1 conditional knockout mice. Further, Trib1 loss augments anti-programmed death-ligand 1 (PD-L1) blockade to improve viral clearance. These data identify Trib1 as an important regulator of CD8+ T EX whose targeting enhances the T KLR effector state and improves checkpoint inhibitor therapy. [Display omitted] • Trib1 deficiency promotes effector gene expression during T cell exhaustion (T EX) • Trib1 deletion in T EX drives clonal expansion of effector-like CD8+ T INT and T KLR • Promotion of T KLR in Trib1 KO is CD8 intrinsic, but viral control requires CD4 cells • Trib1 deletion improves viral control during PD-L1 blockade McClory et al. demonstrate that deletion of Trib1 in T cells promotes clonal expansion of exhausted CD8+ T INT and T KLR cells with an effector-like transcriptional program during chronic LCMV infection. Trib1 deletion improves viral control during PD-L1 blockade, suggesting that targeting Trib1 may improve outcomes during chronic infection and cancer. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF